Roche Makes Tocilizumab Launch Prediction As Biosimilars Progress
One Analyst Suggests: ‘There Have Been Filings’
Executive Summary
Roche gave small insight into its expectations around biosimilar competition for its Actemra/RoActemra (tocilizumab) treatment for inflammatory diseases. Extraordinary demand for the biologic led sales to skyrocket by 143% in the third quarter and caused supply constraints for the originator.
You may also be interested in...
Biogen’s RoActemra Biosimilar Begins EU Approvals Process
The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.
Celltrion Gets Ready To Push Tocilizumab Into Phase III
Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.
Biogen and Bio-Thera Report Progress On Tocilizumab
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.